Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EPS (Weighted Average and Diluted) (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.6 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 27.66% to -$0.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.7 through Dec 2025, up 31.37% year-over-year, with the annual reading at -$0.71 for FY2025, 30.39% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.6 in Q4 2025 for Immunocore Holdings, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.17 in Q3 2024 to a low of -$0.6 in Q4 2025.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.24 across 3 years, with a median of -$0.29 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 750.0% in 2024 and later tumbled 102.29% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.4 in 2023, then dropped by 17.5% to -$0.47 in 2024, then decreased by 27.66% to -$0.6 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for IMCR at -$0.6 in Q4 2025, -$0.0 in Q3 2025, and -$0.2 in Q2 2025.